Skip to Content

Notice

Agency Information Collection Activities: Proposed Collection; Reports and Records Under Prescription Drug Marketing Act of 1987

Document Details

Information about this document as published in the Federal Register.

Enhanced Content

Relevant information about this document from Regulations.gov provides additional context. This information is not part of the official Federal Register document.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

AGENCY:

Food and Drug Administration, HHS.

ACTION:

Notice.

SUMMARY:

The Food and Drug Administration (FDA) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (the PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the reporting and recordkeeping requirements contained in the regulations implementing the Prescription Drug Marketing Act of 1987 (PDMA).

DATES:

Submit either electronic or written comments on the collection of information by August 5, 2011.

ADDRESSES:

Submit electronic comments on the collection of information to http://www.regulations.gov. Submit written comments on the collection of information to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number found in brackets in the heading of this document.

Start Further Info

FOR FURTHER INFORMATION CONTACT:

Elizabeth Berbakos, Office of Information Management, Food and Drug Administration, 1350 Piccard Dr., P150-400B, Rockville, MD 20850, 301-796-3792, Elizabeth.Berbakos@fda.hhs.gov.

End Further Info End Preamble Start Supplemental Information

SUPPLEMENTARY INFORMATION:

Under the PRA (44 U.S.C. 3501-3520), Federal Agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. “Collection of information” is defined in 44 U.S.C. 3502(3) and 5 CFR 1320.3(c) and includes Agency requests or requirements that members of the public submit reports, keep records, or provide information to a third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A)) requires Federal Agencies to provide a 60-day notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, before submitting the collection to OMB for approval. To comply with this requirement, FDA is publishing notice of the proposed collection of information set forth in this document.

With respect to the following collection of information, FDA invites comments on these topics: (1) Whether the proposed collection of information is necessary for the proper performance of FDA's functions, including whether the information will have practical utility; (2) the accuracy of FDA's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques, when appropriate, and other forms of information technology.

Prescription Drug Marketing Act of 1987; Administrative Procedures, Policies, and Requirements—21 CFR Part 203 (OMB Control Number 0910-0435)—Extension

FDA is requesting OMB approval under the PRA (44 U.S.C. 3501-3520) for the reporting and recordkeeping requirements contained in the regulations implementing the Prescription Drug Marketing Act of 1987 (PDMA) (Public Law 100-293). PDMA was intended to ensure that drug products purchased by consumers are safe and effective and to avoid an unacceptable risk that counterfeit, adulterated, misbranded, subpotent, or expired drugs are sold. Start Printed Page 32363

PDMA was enacted by Congress because there were insufficient safeguards in the drug distribution system to prevent the introduction and retail sale of substandard, ineffective, or counterfeit drugs, and that a wholesale drug diversion submarket had developed that prevented effective control over the true sources of drugs.

Congress found that large amounts of drugs had been reimported into the United States as U.S. goods returned causing a health and safety risk to U.S. consumers because the drugs may become subpotent or adulterated during foreign handling and shipping. Congress also found that a ready market for prescription drug reimports had been the catalyst for a continuing series of frauds against U.S. manufacturers and had provided the cover for the importation of foreign counterfeit drugs.

Congress also determined that the system of providing drug samples to physicians through manufacturers' representatives had resulted in the sale to consumers of misbranded, expired, and adulterated pharmaceuticals.

The bulk resale of below-wholesale priced prescription drugs by health care entities for ultimate sale at retail also helped to fuel the diversion market and was an unfair form of competition to wholesalers and retailers who had to pay otherwise prevailing market prices.

FDA is requesting OMB approval for the following reporting and recordkeeping requirements:

Table 1—Reporting Requirements

21 CFR 203.11Applications for reimportation to provide emergency medical care.
21 CFR 203.30(a)(1) and (b)Drug sample requests (drug samples distributed by mail or common carrier).
21 CFR 203.30(a)(3), (a)(4), and (c)Drug sample receipts (receipts for drug samples distributed by mail or common carrier).
21 CFR 203.31(a)(1) and (b)Drug sample requests (drug samples distributed by means other than the mail or a common carrier).
21 CFR 203.31(a)(3), (a)(4), and (c)Drug sample receipts (drug samples distributed by means other than the mail or a common carrier).
21 CFR 203.37(a)Investigation of falsification of drug sample records.
21 CFR 203.37(b)Investigation of a significant loss or known theft of drug samples.
21 CFR 203.37(c)Notification that a representative has been convicted of certain offenses involving drug samples.
21 CFR 203.37(d)Notification of the individual responsible for responding to a request for information about drug samples.
21 CFR 203.39(g)Preparation by a charitable institution of a reconciliation report for donated drug samples.

Table 2—Recordkeeping Requirements

21 CFR 203.23(a) and (b)Credit memo for returned drugs.
21 CFR 203.23(c)Documentation of proper storage, handling, and shipping conditions for returned drugs.
21 CFR 203.30(a)(2) and 203.31(a)(2)Verification that a practitioner requesting a drug sample is licensed or authorized by the appropriate State authority to prescribe the product.
21 CFR 203.31(d)(1) and (d)(2)Contents of the inventory record and reconciliation report required for drug samples distributed by representatives.
21 CFR 203.31(d)(4)Investigation of apparent discrepancies and significant losses revealed through the reconciliation report.
21 CFR 203.31(e)Lists of manufacturers' and distributors' representatives.
21 CFR 203.34Written policies and procedures describing administrative systems.
21 CFR 203.37(a)Report of investigation of falsification of drug sample records.
21 CFR 203.37(b)Report of investigation of significant loss or known theft of drug samples.
21 CFR 203.38(b)Records of drug sample distribution identifying lot or control numbers of samples distributed. (The information collection in 21 CFR 203.38(b) is already approved under OMB Control Number 0910-0139).
21 CFR 203.39(d)Records of drug samples destroyed or returned by a charitable institution.
21 CFR 203.39(e)Record of drug samples donated to a charitable institution.
21 CFR 203.39(f)Records of donation and distribution or other disposition of donated drug samples.
21 CFR 203.39(g)Inventory and reconciliation of drug samples donated to charitable institutions.
21 CFR 203.50(a)Drug origin statement.
21 CFR 203.50(b)Retention of drug origin statement for 3 years.
21 CFR 203.50(d)List of authorized distributors of record.

The reporting and recordkeeping requirements are intended to help achieve the following goals: (1) To ban the reimportation of prescription drugs produced in the United States, except when reimported by the manufacturer or under FDA authorization for emergency medical care; (2) to ban the sale, purchase, or trade, or the offer to sell, purchase, or trade, of any prescription drug sample; (3) to limit the distribution of drug samples to practitioners licensed or authorized to prescribe such drugs or to pharmacies of hospitals or other health care entities at the request of a licensed or authorized practitioner; (4) to require licensed or authorized practitioners to request prescription drug samples in writing; (5) to mandate storage, handling, and recordkeeping requirements for prescription drug samples; (6) to prohibit, with certain exceptions, the sale, purchase, or trade of, or the offer to sell, purchase, or trade, prescription drugs that were purchased by hospitals or other health care entities, or which were donated or supplied at a reduced price to a charitable organization; (7) to require unauthorized wholesale distributors to provide, prior to the wholesale distribution of a prescription drug to another wholesale distributor or Start Printed Page 32364retail pharmacy, a statement identifying each prior sale, purchase, or trade of the drug.

FDA estimates the burden of this collection of information as follows:

Table 3—Estimated Annual Reporting Burden1

21 CFR sectionNumber of respondentsNumber of responses per respondentTotal annual responsesAverage burden per response (in hours) 2Total hours
203.1111130/60.50
203.30(a)(1) and (b)61,96112743,5324/6044,612
203.30(a)(3), (a)(4), and (c)61,96112743,5324/6044,612
203.31(a)(1) and (b)232,35513531,367,9252/601,254,717
203.31(a)(3), (a)(4), and (c)232,35513531,367,9252/60941,038
203.37(a)50420015/6050
203.37(b)50402,00015/60500
203.37(c)11111
203.37(d)501505/604
203.39(g)11111
Total2,285,535.50
1 There are no capital costs or operating and maintenance costs associated with this collection of information.
2 Burden estimates of less than 1 hour are expressed as a fraction of an hour in the format “[number of minutes per response]/60”.

Table 4—Estimated Annual Recordkeeping Burden1

21 CFR sectionNumber of recordkeepersNumber of records per recordkeeperTotal annual recordsAverage burden per recordkeeping (in hours) 2Total hours
203.23(a) and (b)31,6765158,38015/6039,595
203.23(c)31,6765158,3805/6012,670
203.30(a)(2) and 203.31(a)(2)2,208100220,80030/60110,400
203.31(d)(1) and (d)(2)2,20812,2084088,320
203.31(d)(4)44214422410,608
203.31(e)2,20812,20812,208
203.3490190403,600
203.37(a)50420061,200
203.37(b)50402,00061,200
203.39(d)65165165
203.39(e)3,22113,22130/601,610
203.39(f)3,22113,221825,768
203.39(g)3,22113,221825,768
203.50(a)12510012,50010/602,125
203.50(b)12510012,50030/606,250
203.50(d)691169121,382
Total332,769
1 There are capital costs or operating and maintenance costs associated with this collection of information.
2 Burden estimates of less than 1 hour are expressed as a fraction of an hour in the format “[number of minutes per response]/60”.
Start Signature

Dated: May 24, 2011.

Leslie Kux,

Acting Assistant Commissioner for Policy.

End Signature End Supplemental Information

[FR Doc. 2011-13442 Filed 6-3-11; 8:45 am]

BILLING CODE 4160-01-P